Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients With Chronic Spontaneous Urticaria. (2024). SKIN The Journal of Cutaneous Medicine, 8(1), s333. https://doi.org/10.25251/skin.8.supp.333